DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells ( Opti-Heps) with functional relevance comparable to human primary cells. Our Opti-Heps effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our Opti-Heps successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.
No data available
No data available
No data available
No data available
No data available
No data available
Protogenia Consulting Ltd offers non-clinical and early clinical development consultancy services, with more than 15 years' outsourcing and project management experience gained through virtual and mid-sized pharmaceutical companies. The services offered include: strategic planning to enable early clinical development and product registration; non-clinical and clinical project management; regulatory submission writing/review/sign-off (e.g. CTA/IND, MAA/NDA, IMPD and IB); and CRO selection and study management – clinical (up to Phase 2) and non-clinical (toxicology, safety pharmacology, ADME, bioanalysis). In addition, we have a broad network of contacts, for expert advice on IP, CMC, analytical services, regulatory affairs and quality assurance.
Qkine was founded in 2016 to produce high-quality growth factors for use in regenerative medicine applications. The company builds on expertise in protein purification and structural biology developed at University of Cambrige and collaborations with the Cambridge stem cell community. We address the need for high-quality growth factors for regenerative medicine and innovate to tackle challenges in stem cell science.
QRC Consultants, experienced professionals dedicated to providing high quality, cost-effective support to biopharmaceutical companies in early clinical development. We offer technical expertise with strengths including: understanding of the regulatory environment governing clinical trials globally; regulatory agency meetings and submissions – trial management, and monitoring and audit of trials; and small molecules, biological and advanced therapies. Services include: quality assurance – setup and maintenance of QMS, GCP audits and agency inspection preparation; regulatory affairs – technical document writing, SME and EU legal representative services, and bespoke procedural and GCP training; and clinical trial support – project management and monitoring.